Sichuan Baili Pharmaceutical Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL

Phase 1

Recruiting

Conditions: Non-Hodgkin Lymphoma
Vascular Immunomother T Cell Lymphoma
NK/T Cell Lymphoma

Interventions: Drug: GNC-038

First Posted Date: 2022-11-28

Last Posted Date: 2024-12-18

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT05627856

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Recruiting

Conditions: Non-hodgkin's Lymphoma

Interventions: Drug: GNC-038

First Posted Date: 2022-11-21

Last Posted Date: 2024-12-18

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT05623982

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Harbin First Hospital, Haerbin, Heilongjing, China
🇨🇳
Qingdao Central Hospital, Qingdao, Shandong, China

A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Phase 1

Recruiting

Conditions: Primary Central Nervous System Lymphoma
Secondary Central Nervous System Lymphoma

Interventions: Drug: GNC-038

First Posted Date: 2022-08-03

Last Posted Date: 2024-07-18

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 33

Registration Number: NCT05485753

Locations: 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳
Beijing GoBroad Boren Hospital, Beijing, Beijing, China

and more 1 locations

A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor
Breast Cancer

Interventions: Drug: BL-B01D1

First Posted Date: 2022-07-22

Last Posted Date: 2024-12-18

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT05470348

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳
Fudan University ShangHai Cancer Center, Shanghai, Shanghai, China

A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

Phase 1

Recruiting

Conditions: Breast Cancer
Locally Advanced or Metastatic Solid Tumor

Interventions: Drug: BL-M07D1

First Posted Date: 2022-07-18

Last Posted Date: 2024-12-19

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 26

Registration Number: NCT05461768

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
Dongguan People's Hospital, Dongguan, Guangdong, China
🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong, Guangzhou, China

and more 4 locations

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors

Phase 1

Recruiting

Conditions: Locally Advanced or Metastatic Urinary Tumors
Other Solid Tumors

Interventions: Drug: BL-B01D1

First Posted Date: 2022-05-26

Last Posted Date: 2024-10-15

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 26

Registration Number: NCT05393427

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

and more 1 locations

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor
Locally Advanced or Metastatic Digestive Tract Tumors

Interventions: Drug: BL-M02D1

First Posted Date: 2022-05-23

Last Posted Date: 2024-11-12

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 26

Registration Number: NCT05385692

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors

Phase 1

Recruiting

Conditions: Breast Cancer

Interventions: Drug: BL-M02D1

First Posted Date: 2022-04-21

Last Posted Date: 2024-07-18

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 26

Registration Number: NCT05339685

Locations: 🇨🇳
Yueyang People's Hospital, Yueyang, Hunan, China
🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China

and more 7 locations

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor

Phase 1

Recruiting

Conditions: Gastrointestinal Tumor

Interventions: Drug: BL-B01D1

First Posted Date: 2022-03-02

Last Posted Date: 2024-12-18

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 96

Registration Number: NCT05262491

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Jinan Central Hospital, Jinan, Shandong, China

and more 3 locations

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

Phase 1

Recruiting

Conditions: Locally Advanced or Metastatic Solid Tumor

Interventions: Drug: BL-B01D1

First Posted Date: 2022-01-18

Last Posted Date: 2024-12-18

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 96

Registration Number: NCT05194982

Locations: 🇨🇳
Shanxi Cancer Hospital, Taiyuan, Shanxi, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

and more 5 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy